文献速递瓣膜病与结构性心脏病心律失常

风湿性二尖瓣手术中左心耳处理策略的对比研究

Exclusion versus preservation of the left atrial appendage in rheumatic mitral valve surgery.
PubMed 文献 · Heart · 2020-05-06

本研究回顾性分析了1997至2016年间接受风湿性二尖瓣手术的1226例房颤患者,比较左心耳保留(836例)与切除(390例)对临床结局的影响。中位随访63.4个月,倾向性匹配后两组死亡和血栓栓塞风险无显著差异;但在未行消融亚组中,左心耳保留者死亡和血栓栓塞风险有升高趋势。

要点

  • 在风湿性二尖瓣手术房颤患者中,左心耳保留与切除的死亡和血栓栓塞风险总体无显著差异。
  • 合并消融治疗时,左心耳保留未增加死亡(HR 0.67)和血栓栓塞(HR 0.47)风险。
  • 未行消融时,左心耳保留者死亡(HR 2.24)和血栓栓塞(HR 4.41)风险有升高趋势,但置信区间宽。

核心结论

  • 在房颤患者接受风湿性二尖瓣手术时,左心耳保留似乎并未增加不良临床事件风险,尤其当联合消融手术时。

研究设计与样本

  • 回顾性队列研究,纳入1997至2016年连续1226例房颤患者(54.5±11.6岁,女性68.2%),左心耳保留836例(68.2%),切除390例(31.8%),采用倾向性匹配调整基线。

主要发现

  • 中位随访63.4个月(IQR 20-111),总体死亡风险为2.77% vs 3.03%/患者年,血栓栓塞风险为0.91% vs 1.02%/患者年,组间无显著差异。
  • 倾向性匹配的258对患者中,死亡(2.77% vs 3.03%/患者年)和血栓栓塞(1.36% vs 0.82%/患者年)结局相当。
  • 消融亚组(n=810)中,调整后死亡HR 0.67(95%CI 0.34-1.32),血栓栓塞HR 0.47(95%CI 0.18-1.26),均无显著差异。
  • 未消融亚组(n=416)中,左心耳保留者调整后死亡HR 2.24(95%CI 0.98-5.13),血栓栓塞HR 4.41(95%CI 0.97-20.1),有升高趋势。

关键数值与推荐

  • 左心耳保留组836例(68.2%),切除组390例(31.8%)。
  • 消融手术在左心耳保留组中506例(60.5%),切除组中304例(77.9%)。

临床怎么用

  • 对于接受风湿性二尖瓣手术的房颤患者,左心耳保留在联合消融时未显示增加死亡和血栓栓塞风险。
  • 在未行消融的患者中,左心耳保留可能与死亡和血栓栓塞风险升高相关,需个体化评估。

局限性

  • 回顾性研究设计,可能存在残留混杂。
  • 未消融亚组的风险估计置信区间宽,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate the impact of left atrial appendage exclusion on clinical outcomes in patients with atrial fibrillation (AF) undergoing rheumatic mitral surgery. METHODS: We retrospectively reviewed 1226 consecutive patients with AF (54.5±11.6 years; 68.2% females) who underwent rheumatic mitral valve (MV) surgery from 1997 to 2016. The left atrial appendage was preserved in 836 (68.2%) and excluded in 390 (31.8%) patients. Surgical AF ablation was performed in 506 (60.5%) and 304 (77.9%) patients with preserved and excluded left atrial appendage, respectively. For baseline adjustment, propensity matching was used. RESULTS: During a median follow-up of 63.4 months (IQRs, 20-111 months), there were no significant intergroup differences in the risks of mortality (2.77% vs 3.03%/patient-years) and thromboembolic events (0.91% vs 1.02%/patient-years). In the 258 pairs of propensity-score matched patients, death (2.77% vs 3.03%/patient-years) and thromboembolism (1.36% vs 0.82%/patient-years) outcomes were comparable for both groups. In a subgroup undergoing ablation (n=810), there were no significant differences in the adjusted risks of death (HR, 0.67; 95% CI, 0.34 to 1.32) and thromboembolism (HR, 0.47; 95% CI, 0.18 to 1.26). In a subgroup not undergoing ablation (n=416), however, left atrial appendage preservation tended to have higher adjusted risks for death (HR, 2.24; 95% CI, 0.98 to 5.13) and thromboembolism (HR, 4.41; 95% CI, 0.97 to 20.1). CONCLUSIONS: Left atrial appendage preservation did not seem to have greater risks of adverse clinical events in patients with AF undergoing rheumatic MV surgery particularly when ablation procedure is combined.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Kim WK, Kim HJ, Kim JB, et al. Exclusion versus preservation of the left atrial appendage in rheumatic mitral valve surgery. Heart. 2020. PMID: 32376607. doi:10.1136/heartjnl-2019-316387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。